SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 325 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,242,668 | -24.5% | 430,974 | -28.7% | 0.06% | -21.5% |
| Q2 2023 | $69,208,541 | -27.2% | 604,336 | -12.4% | 0.08% | -28.2% |
| Q1 2023 | $95,049,178 | +3.6% | 689,612 | -2.6% | 0.11% | +0.9% |
| Q4 2022 | $91,731,455 | -9.5% | 707,946 | -22.8% | 0.11% | -16.8% |
| Q3 2022 | $101,391,000 | +95.9% | 917,242 | +32.9% | 0.13% | +104.7% |
| Q2 2022 | $51,744,000 | -23.0% | 690,295 | -19.7% | 0.06% | -7.2% |
| Q1 2022 | $67,164,000 | -17.0% | 859,748 | -4.4% | 0.07% | -12.7% |
| Q4 2021 | $80,960,000 | -5.8% | 899,056 | -3.2% | 0.08% | -14.1% |
| Q3 2021 | $85,933,000 | +26.7% | 929,208 | +6.5% | 0.09% | +26.0% |
| Q2 2021 | $67,829,000 | +2.7% | 872,292 | -1.5% | 0.07% | -8.8% |
| Q1 2021 | $66,024,000 | -27.8% | 885,871 | +65.1% | 0.08% | -33.9% |
| Q4 2020 | $91,454,000 | +10.9% | 536,417 | -8.6% | 0.12% | -8.3% |
| Q3 2020 | $82,456,000 | -23.1% | 587,166 | -12.2% | 0.13% | -29.0% |
| Q2 2020 | $107,273,000 | +106.8% | 669,036 | +26.1% | 0.19% | +57.6% |
| Q1 2020 | $51,882,000 | -32.9% | 530,378 | -11.5% | 0.12% | -10.6% |
| Q4 2019 | $77,291,000 | +53.3% | 598,968 | -10.5% | 0.13% | +38.9% |
| Q3 2019 | $50,413,000 | -62.0% | 669,320 | -23.4% | 0.10% | -62.0% |
| Q2 2019 | $132,783,000 | +1032.1% | 873,861 | +788.0% | 0.25% | +987.0% |
| Q1 2019 | $11,729,000 | -71.4% | 98,403 | -73.8% | 0.02% | -76.3% |
| Q4 2018 | $40,990,000 | +6.9% | 375,605 | +58.2% | 0.10% | +36.6% |
| Q3 2018 | $38,340,000 | +356.0% | 237,387 | +273.2% | 0.07% | +317.6% |
| Q2 2018 | $8,407,000 | +118.5% | 63,605 | +22.5% | 0.02% | +88.9% |
| Q1 2018 | $3,848,000 | +61.3% | 51,937 | +21.1% | 0.01% | +50.0% |
| Q4 2017 | $2,385,000 | -8.8% | 42,870 | -25.7% | 0.01% | -14.3% |
| Q3 2017 | $2,616,000 | +149.6% | 57,668 | +85.5% | 0.01% | +133.3% |
| Q2 2017 | $1,048,000 | +99.2% | 31,094 | +74.9% | 0.00% | +200.0% |
| Q1 2017 | $526,000 | -32.6% | 17,778 | -37.5% | 0.00% | -50.0% |
| Q4 2016 | $780,000 | – | 28,451 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |